8-K: Capricor Therapeutics Reports Positive Progress in DMD Program and Exosome Platform Development

Capricor Therapeutics announced the completion of enrollment for the Phase 3 HOPE-3 trial (Cohort A) for their Duchenne muscular dystrophy treatment, CAP-1002, and provided updates on their exosome platform.

Summary

• Capricor Therapeutics reported its first quarter 2024 financial results and provided a corporate update, highlighting advancements in their CAP-1002 cell therapy program for Duchenne muscular dystrophy (DMD).
• Enrollment for Cohort A of the Phase 3 HOPE-3 trial is complete, with 61 subjects randomized to either CAP-1002 or placebo.
• The company received a $10 million milestone payment from Nippon Shinyaku due to a positive outcome from the interim futility analysis for Cohort A.
• Capricor had a positive Type-B CMC FDA meeting, aligning on comparability between drug product manufactured at two different facilities.
• A Type-B clinical FDA meeting is scheduled for May 2024 to discuss a pre-BLA meeting and rolling BLA schedule.
• The company plans to report 3-year data from the HOPE-2 Open-Label Extension (OLE) trial in the second quarter of 2024.
• Capricor's StealthX exosome-based multivalent vaccine for SARS-CoV-2 was selected for Project NextGen, with NIAID funding a Phase 1 clinical trial.
• First quarter 2024 revenue was $4.9 million, compared to $3.0 million in the first quarter of 2023, primarily from the Nippon Shinyaku agreement.
• Operating expenses for the first quarter of 2024 were $15.2 million, compared to $11.2 million for the first quarter of 2023.
• The company reported a net loss of $9.8 million, or $0.31 per share, for the first quarter of 2024, compared to a net loss of $7.8 million, or $0.31 per share, for the first quarter of 2023.
• Capricor's cash, cash equivalents, and marketable securities totaled approximately $39.9 million as of March 31, 2024.
• The company believes its current resources will be sufficient to cover expenses into the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the progress in clinical trials, regulatory alignment, and strategic partnerships. However, the increased net loss and operating expenses temper the overall optimism.

Positives

• The completion of enrollment for Cohort A of the Phase 3 HOPE-3 trial is a significant milestone.
• The $10 million milestone payment from Nippon Shinyaku validates the progress of the CAP-1002 program.
• FDA alignment on CMC comparability is a major step towards BLA submission.
• The upcoming Type-B clinical FDA meeting provides an opportunity to discuss expedited approval pathways.
• The NIAID collaboration for the StealthX vaccine provides non-dilutive funding for a Phase 1 trial.
• The increase in revenue compared to the same quarter last year is a positive sign.
• The company's cash position is stable, providing runway into the first quarter of 2025.

Negatives

• The company reported a net loss of $9.8 million for the first quarter of 2024, which is higher than the $7.8 million loss in the same quarter of 2023.
• Operating expenses increased to $15.2 million in the first quarter of 2024, compared to $11.2 million in the first quarter of 2023.

Risks

• The success of the CAP-1002 program is dependent on positive results from the HOPE-3 trial and regulatory approvals.
• The company's financial outlook is based on current plans and excludes potential milestone payments and strategic use of capital.
• The development of the StealthX exosome platform is subject to clinical trial success and regulatory approvals.
• There are risks associated with the manufacturing and commercialization of CAP-1002.
• The company's future success is dependent on securing additional partnerships and non-dilutive funding.

Future Outlook

Capricor believes its current cash resources will be sufficient to cover anticipated expenses and capital requirements into the first quarter of 2025, excluding potential milestone payments and strategic use of capital.

Management Comments

• Capricor continues to make tremendous progress across our pipeline marked by significant advancements in our CAP-1002 cell therapy program for the treatment of Duchenne muscular dystrophy (DMD), said Linda Marbn, Ph.D., Capricors chief executive officer.
• We are appreciative of the FDAs continued guidance under our RMAT designation and we will provide further updates on our plans as they become available.
• We continue to work diligently with our partner, Nippon Shinyaku (U.S. subsidiary: NS Pharma, Inc.) as we prepare for the potential launch of CAP-1002.
• We continue our efforts to advance our proprietary StealthX exosome platform to leverage exosomes for our vaccine program as well as for therapeutic development.

Industry Context

This announcement highlights Capricor's progress in the competitive field of rare disease therapeutics, particularly in Duchenne muscular dystrophy, where there is a high unmet medical need. The company's focus on cell and exosome-based therapies aligns with current trends in biotechnology.

Comparison to Industry Standards

• Capricor's progress with CAP-1002 in DMD is comparable to other companies developing advanced therapies for this disease, such as Sarepta Therapeutics and PTC Therapeutics.
• The completion of enrollment for Cohort A of the Phase 3 trial is a significant milestone, similar to other companies reaching late-stage clinical development.
• The collaboration with NIAID for the exosome-based vaccine is a unique approach, differentiating Capricor from other companies focused solely on cell therapies.
• The financial results show increased revenue due to the Nippon Shinyaku agreement, which is a common strategy for biotech companies to secure funding and commercialization partnerships.
• The reported net loss is typical for a biotech company in the clinical development stage, as significant R&D expenses are incurred.

Stakeholder Impact

• Shareholders will be impacted by the progress of clinical trials and regulatory approvals, as well as the company's financial performance.
• Employees will be impacted by the company's growth and development of new therapies.
• Patients with Duchenne muscular dystrophy and other rare diseases will be impacted by the potential availability of new treatments.
• Partners such as Nippon Shinyaku will be impacted by the commercialization of CAP-1002.
• The collaboration with NIAID will impact the development of the StealthX vaccine.

Next Steps

• Capricor plans to have a Type-B clinical FDA meeting in May 2024 to discuss requests for a pre-BLA meeting and rolling BLA schedule.
• The company plans to report 3-year HOPE-2 OLE data in the second quarter of 2024.
• Capricor plans to announce further updates with respect to next steps for HOPE-3 (Cohort B), when available.
• The company plans to report topline data from HOPE-3 (Cohort A) in the fourth quarter of 2024.
• Capricor will continue to explore opportunities for additional partnerships outside of the U.S. and Japan to support the potential commercialization of CAP-1002 in DMD.
• The company plans to provide updates on the NIAID collaboration for the StealthX vaccine as they become available.
• NIAID plans to initiate the Phase 1 clinical trial in late 2024, subject to regulatory approval.
• Capricor will continue to explore opportunities for partnerships and non-dilutive sources of funding to support advancement of the StealthX exosome platform technology.

Key Dates

Keywords

CAP-1002, Duchenne muscular dystrophy, DMD, StealthX, exosomes, cell therapy, FDA, BLA, Nippon Shinyaku, clinical trial, milestone payment, vaccine, NIAID, CMC, regulatory approval